Form 4: Pliant Therapeutics CEO Sells Shares to Cover Tax Obligations

Pliant Therapeutics CEO, Bernard Coulie, sold 52,419 shares of common stock to cover tax liabilities related to vesting restricted stock units.

Summary

• Pliant Therapeutics CEO, Bernard Coulie, executed a sale of 52,419 shares of common stock on January 17, 2025.
• The sale was conducted at a weighted average price of $11.2011 per share.
• The transaction was part of a larger sale by a group of employees to cover withholding tax obligations related to vesting restricted stock units.
• The sale was executed under a Rule 10b5-1 trading plan.
• Following the transaction, Coulie directly owns 430,517 shares and indirectly owns 409,317 shares through The Coulie/Leyman Family Trust.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction for tax purposes, not indicative of a change in the company's prospects. The use of a 10b5-1 plan suggests the sale was planned and not based on new information.

Risks

• Sales by insiders can sometimes be perceived negatively by the market, although this sale was for tax purposes and under a pre-arranged plan.

Industry Context

Insider sales are a common occurrence, especially when executives need to cover tax obligations related to equity compensation. The use of a 10b5-1 plan is a standard practice to avoid accusations of insider trading.

Comparison to Industry Standards

• The use of a Rule 10b5-1 trading plan is a common practice among executives at publicly traded companies to manage their stock sales and avoid insider trading concerns.
• Similar sales are often seen at other biotech companies when restricted stock units vest and create tax liabilities for employees.

Stakeholder Impact

• The sale may have a minor impact on the stock price, but it is unlikely to be significant given the pre-planned nature of the transaction.

Key Dates

Keywords

Pliant Therapeutics, Bernard Coulie, insider trading, stock sale, Form 4, Rule 10b5-1, tax obligations, restricted stock units